ProMetic, Novartis to develop vaccine purification product

novartisDec 4 (Reuters) - ProMetic Life Sciences Inc. (PLI.TO: Quote, Profile , Research) said its UK unit has entered into an agreement with Novartis (NVS.N: Quote, Profile , Research) to develop a synthetic-ligand affinity adsorbent for the purification of protein vaccines.

ProMetic will receive funding from Novartis to screen its chemical combinatorial libraries for ligands suitable for the purification of a new vaccine product developed by Novartis and currently undergoing clinical trials, it added. (Reporting by Sweta Singh in Bangalore)

© Reuters 2006